o

 
Meticulous Research®—a leading global market research company, published a research report titled, ‘Africa IVD Market by Product & Solution, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), End User - Forecast to 2030.’
Download Free sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5415
According to this latest publication from Meticulous Research®, the Africa in vitro diagnostics (IVD) market is expected to reach $1.49 billion by 2030, at a CAGR of 2.8% from 2023 to 2030. The high prevalence of infectious diseases, the rising burden of chronic diseases, the rising initiatives to support the healthcare sector, and the growing awareness regarding the importance of early disease diagnosis drive the growth of the Africa IVD market. However, poor healthcare facilities and infrastructure in African countries are a major challenge to the market's growth.
The Africa IVD market is segmented based on Product Category (Reagents, & Kits, Instruments, and Software & Services), Technology (Molecular Diagnostics, Point-of-Care Diagnostics, Immunoassay/Immunochemistry, Biochemistry/Clinical Chemistry, Whole Blood Glucose Monitoring, Hematology, Microbiology, Coagulation & Hemostasis, and Other IVD Technologies), Application (Infectious Diseases, Oncology, Diabetes, Cardiology, Nephrology, Autoimmune Disorders, and Other Applications), Diagnostic Approach (Lab Testing, Point-of-care Testing, and OTC/Self-testing), and End User (Hospitals & Clinics, Diagnostic Laboratories, Home Healthcare, and Other End Users), and Geography. The study also evaluates industry competitors and analyzes their market shares.
Based on product category, in 2023, the reagents & kits segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the frequent utilization of IVD assays & kits in the diagnosis and management of various chronic diseases, the commercial availability of a wide range of reagents & consumables for the diagnosis of various communicable and non-communicable diseases, the increasing awareness about the importance of early diagnosis, and the increase in the volume of testing for infectious diseases such as COVID-19, malaria, and influenza.
Based on technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the higher preference for molecular diagnostics due to their benefits, such as faster turnaround time, higher diagnosis accuracy, and high sensitivity.
Based on application, in 2023, the infectious diseases segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the significant burden of emerging and re-emerging infections in Africa and favorable initiatives to improve diagnostic rates.
Speak to analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5415
Based on diagnostic approach, in 2023, the lab testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the availability of several IVD tests in laboratories and the higher accuracy of laboratory testing.
Based on end user, in 2023, the hospitals & clinics testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the high patient inflow to the hospitals.
Geographic Review
This research report analyzes the market across major African countries and provides a comprehensive analysis of South Africa, Algeria, Nigeria, Kenya, Morocco, Tunisia, Tanzania, Egypt, and the rest of Africa.
Key Players
Key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).
Quick Buy: https://www.meticulousresearch.com/Checkout/24576471
Key questions answered in the report:
• What is the total sales value generated by the in vitro diagnostics manufacturers in Africa?
• At what rate the demand for in vitro diagnostics products is projected to grow for the next 5–7 years? Also, what was the historical market size and growth of Africa’s in vitro diagnostics market?
• What are the major factors impacting the growth of this market at the country level? What are the major opportunities for existing market players and new entrants?
• Which are the high-growth market segments in product & solution, technology, application, diagnostics approach, end user, and countries?
• Which countries are expected to offer significant growth opportunities for the vendors operating in vitro diagnostics market in Africa?
• Who are the major players in Africa’s in vitro diagnostics market? What product/service do they specifically offer in the IVD industry?
• What are the recent developments in the in vitro diagnostics market in Africa, and how are these strategic developments creating a regional impact in this market?
Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research